Moderna (MRNA) Other Non Operating Income: 2018-2025
Historic Other Non Operating Income for Moderna (MRNA) over the last 7 years, with Jun 2025 value amounting to $8.0 million.
- Moderna's Other Non Operating Income rose 129.63% to $8.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$37.0 million, marking a year-over-year increase of 72.79%. This contributed to the annual value of -$87.0 million for FY2024, which is 29.84% up from last year.
- Latest data reveals that Moderna reported Other Non Operating Income of $8.0 million as of Q2 2025, which was up 300.00% from -$4.0 million recorded in Q1 2025.
- Moderna's Other Non Operating Income's 5-year high stood at $14.0 million during Q2 2023, with a 5-year trough of -$51.0 million in Q3 2023.
- In the last 3 years, Moderna's Other Non Operating Income had a median value of -$23.0 million in 2024 and averaged -$20.7 million.
- Its Other Non Operating Income has fluctuated over the past 5 years, first crashed by 900.00% in 2021, then skyrocketed by 207.69% in 2023.
- Moderna's Other Non Operating Income (Quarterly) stood at -$7.0 million in 2021, then tumbled by 71.43% to -$12.0 million in 2022, then tumbled by 225.00% to -$39.0 million in 2023, then increased by 25.64% to -$29.0 million in 2024, then spiked by 129.63% to $8.0 million in 2025.
- Its Other Non Operating Income stands at $8.0 million for Q2 2025, versus -$4.0 million for Q1 2025 and -$29.0 million for Q4 2024.